Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer
作者： Giulia M. Stella , Alessandra Gentile , Alice Balderacchi , Federica Meloni , Melissa Milan
DOI: 10.1186/S12967-016-1008-4
关键词: Epithelial–mesenchymal transition 、 Malignant transformation 、 Effective treatment 、 Lung Disorder 、 Pathology 、 Idiopathic pulmonary fibrosis 、 Cancer 、 Etiology 、 Medicine 、 Invasive growth
摘要: Background Idiopathic pulmonary fibrosis (IPF) identifies a specific lung disorder characterized by chronic, progressive fibrosing interstitial pneumonia of unknown etiology, which lacks effective treatment. According to the current pathogenic perspective, aberrant proliferative events in IPF resemble those occurring during malignant transformation.
biomedcentral.com
springer.com
core.ac.uk
elsevier.com
unipv.it参考文章(170)
W. M. Mars, G. K. Michalopoulos, R. Zarnegar, Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. American Journal of Pathology. ,vol. 143, pp. 949- 958 ,(1993)
Masahide Tokunou, Toshiro Niki, Keisuke Eguchi, Sanae Iba, Hitoshi Tsuda, Tesshi Yamada, Yoshihiro Matsuno, Haruhiko Kondo, Yukihito Saitoh, Hiroji Imamura, Setsuo Hirohashi, c-MET Expression in Myofibroblasts: Role in Autocrine Activation and Prognostic Significance in Lung Adenocarcinoma American Journal of Pathology. ,vol. 158, pp. 1451- 1463 ,(2001) , 10.1016/S0002-9440(10)64096-5
Fadila Guessous, Alex Kofman, David Schiff, Ying Zhang, Roger Abounader, XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC IDrugs : the investigational drugs journal. ,vol. 13, pp. 112- 121 ,(2010)
Sara M. Tolaney, Sally Tan, Hao Guo, William Barry, Eliezer Van Allen, Nikhil Wagle, Jane Brock, Katherine Larrabee, Cloud Paweletz, Elena Ivanova, Pasi Janne, Beth Overmoyer, John J. Wright, Geoffrey I. Shapiro, Eric P. Winer, Ian E. Krop, Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer Investigational New Drugs. ,vol. 33, pp. 1108- 1114 ,(2015) , 10.1007/S10637-015-0269-8
Agata M. Wasik, Jerzy Grabarek, Aleksandar Pantovic, Artur Cieślar-Pobuda, Hamid R. Asgari, Caspar Bundgaard-Nielsen, Mehrdad Rafat, Ian M.C. Dixon, Saeid Ghavami, Marek J. Łos, Reprogramming and carcinogenesis: parallels and distinctions International Review of Cell and Molecular Biology. ,vol. 308, pp. 167- 203 ,(2014) , 10.1016/B978-0-12-800097-7.00005-1
Hsiu-Mei Chen, Chia-Hua Tsai, Wen-Chun Hung, Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling Oncotarget. ,vol. 6, pp. 14940- 14952 ,(2015) , 10.18632/ONCOTARGET.3613
Giuseppe Aprile, Francesco Leone, Mariaelena Casagrande, Donatella Marino, Gianpiero Fasola, Riccardo Gianpieri, Luca Faloppi, Mario Scartozzi, Stefano Cascinu, Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology OncoTargets and Therapy. ,vol. 8, pp. 1149- 1156 ,(2015) , 10.2147/OTT.S82624
Camillo Porta, Palma Giglione, Alessandra Ferrari, Francesca Reversi, Wanda Liguigli, Ilaria Imarisio, Carlo Ganini, Tivantinib (ARQ197) in hepatocellular carcinoma Expert Review of Anticancer Therapy. ,vol. 15, pp. 615- 622 ,(2015) , 10.1586/14737140.2015.1050383
S. GIORDANO, A. MAFFE, T. A. WILLIAMS, S. ARTIGIANI, P. GUAL, A. BARDELLI, C. BASILICO, P. MICHIELI, P. M. COMOGLIO, Different point mutations in the met oncogene elicit distinct biological properties. The FASEB Journal. ,vol. 14, pp. 399- 406 ,(2000) , 10.1096/FASEBJ.14.2.399
Mansoureh Sameni, Elizabeth A. Tovar, Curt J. Essenburg, Anita Chalasani, Erik S. Linklater, Andrew Borgman, David M. Cherba, Arulselvi Anbalagan, Mary E. Winn, Carrie R. Graveel, Bonnie F. Sloane, Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models Clinical Cancer Research. ,vol. 22, pp. 923- 934 ,(2016) , 10.1158/1078-0432.CCR-15-0187